Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Assessment of therapeutic effect of liraglutide in newly established cell culture model of non- alcoholic and drug-induced fatty liver disease (CROSBI ID 721168)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Omanovic Kolaric, Tea ; Nincevic, V ; Kizivat, Tomislav ; Zjalic, Milorad ; Kuna, Lucija ; Bilic- Curcic, Ines ; Smolic, Martina Assessment of therapeutic effect of liraglutide in newly established cell culture model of non- alcoholic and drug-induced fatty liver disease // Journal of Hepatology / Angeli, Paolo (ur.). Elsevier, 2022. str. 718-719 doi: 10.1016/S0168-8278(22)01755-X

Podaci o odgovornosti

Omanovic Kolaric, Tea ; Nincevic, V ; Kizivat, Tomislav ; Zjalic, Milorad ; Kuna, Lucija ; Bilic- Curcic, Ines ; Smolic, Martina

engleski

Assessment of therapeutic effect of liraglutide in newly established cell culture model of non- alcoholic and drug-induced fatty liver disease

Background and aims: The impact of non-alcoholic fatty liver disease (NAFLD) on global health is becoming more significant with the growing incidence of obesity and drugs consumption. Therefore, more research is necessary in order to enlighten underlying pathophysiologic mechanisms for these conditions and possible therapeutic approaches. Aims of our study were to establish reliable in vitro models of non-alcoholic and drug-induced fatty liver disease (DIFLD) and also to investigate possible therapeutic solutions in these in vitro models. Method: HuH7 cell culture models of NAFLD and DIFLD were established by incubation of Huh7 cells with 0, 5 mM oleic acid (OA), 5 μM to 20 μM of amiodarone, 1 μM to 10 μM of tamoxifen for various time periods (24 h, 48 h), respectively. Cells where cotreated with 1 nM to 100 nM of liraglutide in order to assess its potential beneficial effect in fatty liver models. Cell viability was measured by MTT ((3- (4, 5-dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium bromide) assay. Changes in cell shape and the extent of hepatosteatosis were assessed by fluorescent microscopy as shown in Figure. Cell nuclei were stained with Hoechst, and fat droplets were stained with Oil-Red-O. Trigliceryde (TG) accumulation was measured by TGO-PAP method and the results were read on the microplate reader. Results: Tamoxifen significantly reduced cell viability in a dosedependent manner after just 24 h treatment, compared to amiodarone and OA. Liraglutide co-treatment improved cell viability and the effect was greater after a longer period of treatment, especially in tamoxifen-treated cells for almost 30% (p <0, 05). Microscopic observations demonstrated microsteatosis as the predominant form of liver cell injury in this time period, with the greatest accumulation of fat in OA model. Accordingly, TG accumulation was highest in OA model, while liraglutide diminished TG accumulation in all three models. Conclusion: This newly established cellular Huh7 model of NAFLD and DIFLD could provide a new tool for further studies on these conditions. Nevertheless, further research is needed to better understand the onset of fatty liver changes, drug toxicity, and the possible role of liraglutide in their treatment.

Liraglutide ; non-alcoholic fatty liver disease ; amiodarone ; tamoxifen ; cell culture

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

718-719.

2022.

objavljeno

10.1016/S0168-8278(22)01755-X

Podaci o matičnoj publikaciji

Journal of Hepatology

Angeli, Paolo

Elsevier

Podaci o skupu

International Liver Congress™ 2022

poster

22.06.2022-26.06.2022

London, Ujedinjeno Kraljevstvo

Povezanost rada

Temeljne medicinske znanosti

Poveznice